Avelas Announces Latest Development, a First for Its Breast Cancer Patients
Aug 05, 2020 AM EDT
San Diego-based clinical-stage biotechnology firm, Avelas Biosciences is set to announce, it has reached Phase 2 of its three-phased clinical study, presenting the firm's cancer-specific fluorescent biomarker, pegloprastide.